Pharmacopeia Collaboration Advances Novel Therapeutic Candidate Into Phase 1 Clinical Trials
2007年2月20日 - 9:30PM
PRニュース・ワイアー (英語)
Pharmacopeia Now Has Four Partnered Programs in Active Clinical
Development PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ --
Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and
development of novel small molecule therapeutics, today announced
that Schering-Plough has initiated a Phase 1 clinical trial in the
United States with PS522501, a compound identified from the
collaboration between the two companies. The compound is being
evaluated as a potential treatment for metabolic diseases. "We now
have three separate programs in clinical trials resulting from our
successful collaboration with Schering-Plough," said Les Browne,
Ph.D., President and Chief Executive Officer of Pharmacopeia. "We
are very pleased to see another candidate enter the clinic and join
the ongoing clinical programs in COPD and oncology."
Schering-Plough is solely responsible for further development and
commercialization of the therapeutic candidate. Pharmacopeia is
eligible to receive milestone payments if the program advances into
late-stage clinical trials and royalties on sales of any resulting
therapeutic products. The most advanced of the programs from the
collaboration between the companies is a CXCR2 antagonist that has
successfully completed Phase 1 clinical development. The further
development of that program is currently being continued by
Schering-Plough in patients suffering from chronic obstructive
pulmonary disease (COPD). ABOUT PHARMACOPEIA Pharmacopeia is
committed to discovering and developing novel therapeutics to
address significant medical needs. The Company has a broad
portfolio advancing towards clinical validation, both independently
and with partners. Pharmacopeia's most advanced internal program is
a dual-acting angiotensin and endothelin receptor antagonist (DARA)
for hypertension and diabetic kidney disease for which a Phase 1
clinical trial is underway. Other internal proprietary programs
address immunoregulation. Four partnered programs are in active
clinical trials: a CXCR2 antagonist for chronic obstructive
pulmonary disease (COPD), p38 MAP kinase inhibitors for rheumatoid
arthritis, an enzyme inhibitor for oncology and a candidate for
metabolic diseases. Four additional partnered compounds are in
preclinical development. Pharmacopeia's discovery, development and
commercialization partnerships are with leading pharmaceutical
companies including GlaxoSmithKline, Bristol-Myers Squibb, Organon,
Schering-Plough, Cephalon, Celgene, and Wyeth. Contact: Brian M.
Posner Executive Vice President and Chief Financial Officer
Pharmacopeia (609)452-3643 This press release, and oral statements
made with respect to information contained in this press release,
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those which express plan,
anticipation, intent, goal, contingency or future development
and/or otherwise are not statements of historical fact. These
statements are based upon management's current expectations and are
subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from
those expressed or implied in such statements. These forward-
looking statements include, but are not limited to, statements
about the successful implementation of Pharmacopeia's strategic
plans, Pharmacopeia's plans to develop PS433540, a compound from
its DARA program, Pharmacopeia's Phase 1 clinical studies with
respect to PS433540, Pharmacopeia's ability to successfully perform
under its collaborations with Cephalon, GlaxoSmithKline, Organon
and Wyeth, Pharmacopeia's ability to build its pipeline of novel
drug candidates through its own internally-funded drug discovery
programs, third party collaborations and in-licensing,
Pharmacopeia's ability to raise additional capital, Pharmacopeia's
expectations concerning the development priorities of its
collaborators, their ability to successfully develop compounds and
its receipt of milestones and royalties from the collaborations,
Pharmacopeia's anticipated operating results, financial condition,
liquidity and capital resources, Pharmacopeia's expectations
concerning the legal protections afforded by U.S. and international
patent law, Pharmacopeia's ability to pursue the development of new
compounds and other business matters without infringing the patent
rights of others, additional competition, and changes in economic
conditions. Further information about these and other relevant
risks and uncertainties may be found in Pharmacopeia's Reports on
Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Pharmacopeia urges you to carefully review and consider
the disclosures found in its filings which are available in the SEC
EDGAR database at http://www.sec.gov/ and from Pharmacopeia at
http://www.pharmacopeia.com/. All forward-looking statements in
this press release and oral statements made with respect to
information contained in this press release are qualified entirely
by the cautionary statements included in this press release and
such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by
such forward-looking statements. These forward- looking statements
speak only as of the date of this press release. Pharmacopeia
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise. DATASOURCE:
Pharmacopeia CONTACT: Brian M. Posner, Executive Vice President and
Chief Financial Officer for Pharmacopeia, +1-609-452-3643, Web
site: http://www.pharmacopeia.com/
Copyright